Active Biotech: Year End Report 2021 : vimarsana.com

FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address unmet medical need in hematological cancers and inflammatory eye disorders. The fourth quarter in particular

Related Keywords

Hans Kolam , Erik Vahtola , Loncode Institute , Active Biotech , Chief Medical Officer , Abuse Regulation , Securities Markets , End Report , Active , Biotech , Ear , Report , 021 ,